ClinicalTrials.gg
CompletedNCT06575959Updated May 29, 2026Results posted

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

A Phase 1 interventional study of Enlicitide in Hepatic Insufficiency and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hepatic Insufficiency by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Hepatic Insufficiency · Merck & Co., Inc.

Enrollment
4th of 10
20 · median 20
Started
2024
the only one that year
Phase 1
10 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, this one is the 4th largest by enrollment, is the only one that started in 2024, is one of 10 in phase 1, and was the 9th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

1 of the 10 studies in Hepatic Insufficiency by Merck & Co., Inc is open now. Recruiting first, the newest first:

Where they have run

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hepatic Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward,

The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to enlicitide in the body when it is given to people with hepatic impairment (HI- meaning the liver does not work properly) and people who are in good health.

This study will have 2 parts. In Part 1, enlicitide will be given to people with moderate HI and people who are in good health. After Part 1, researchers may decide to include people who have mild HI and compare what happens to enlicitide in the body with people who are in good health.

03

Conditions studied

  • Hepatic Insufficiency
  • Hepatic Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

All participants:

  • Has been a non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to starting the study
  • Has (BMI) ≥ 18.0 and ≤ 40.0 kg/m2

Participants with moderate or mild HI:

  • Diagnosis of chronic (> 6 months) and stable (no sudden or severe episodes of illness due to worsening liver function in the past 2 months) hepatic insufficiency, and features cirrhosis (liver scarring) due to any cause.
  • Is generally in good health with the exception of HI.

Healthy Control Participants:

  • Medically healthy with no medical history, physical examination, or clinical laboratory profiles

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

All participants:

  • History of gastrointestinal disease which may affect food and drug absorption, or has had a gastric bypass or similar surgery.
  • History of cancer
  • Consumes greater than 3 servings of alcoholic beverages per day.
  • Is on statin background therapy.

Participants with moderate or mild HI:

  • Severe complications of liver disease within 3 months of entering the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment (HI)

    Participants will receive a single oral dose of enlicitide on Day 1

    Drug: Enlicitide

  • Experimental
    Healthy Controls

    Participants will receive a single oral dose of enlicitide on Day 1

    Drug: Enlicitide

  • Experimental
    Mild HI

    Participants will receive a single oral dose of enlicitide on Day 1

    Drug: Enlicitide

Interventions

  • Oral tablet

    Also known as: enlicitide decanoate, MK-0616/sodium caprate

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide

    Blood samples were collected at pre-specified time points to determine the AUC0-inf of enlicitide in plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest, last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  2. Maximum Concentration (Cmax) of Enlicitide

    Blood samples were collected at pre-specified time points to determine the Cmax of enlicitide in participant's plasma. Cmax was defined as the maximum observed concentration of enlicitide in plasma after the administration of a given dose.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide

    Blood samples were collected at pre-specified time points to determine the AUC0-24 of encilitide. AUC0-24 of encilitide was defined as the area under the concentration-time curve from time 0 to the 24 hours after the dosing of encilitide.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, and 24 hours postdose

  2. Area Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma

    Blood samples were collected at pre-specified time points to determine the AUC0-last of enlicitide in participant's plasma. AUC0 to last of enlicitide was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  3. Time to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide

    Blood samples were collected at pre-specified time points to determine the tmax of enlicitide in participant's plasma. Tmax was defined as time to the maximum concentration of enlicitide reached.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  4. Apparent Terminal Half-life (t1/2) of Enlicitide

    Blood samples were collected at pre-specified timepoints to determine the t1/2 of enlicitide. t1/2 was defined as the time required to divide the enlicitide plasma concentration by two after reaching pseudo-equilibrium, following a single dose of enlicitide.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  5. Apparent Clearance (CL/F) of Enlicitide

    Blood samples were collected at pre-specified timepoints to determine the CL/F of enlicitide. CL/F was the apparent total clearance of enlicitide in plasma over time, assessed as the rate at which enlicitide was removed from the plasma.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  6. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide

    Blood samples were collected at pre-specified timepoints to determine the Vz/F of enlicitide. Vz/F was the apparent volume of distribution of enlicitide between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide that would need to be uniformly distributed to achieve the desired plasma drug concentration.

    Time frame: Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose

  7. Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experienced a TEAE were reported.

    Time frame: Up to approximately 6 weeks

  8. Number of Participants Who Experienced An Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

    Time frame: Up to approximately 6 weeks

  9. Number of Participants Who Discontinued Study Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported..

    Time frame: Up to approximately 6 weeks

07

Results

Posted May 29, 2026

Participant flow

Participants with chronic, stable hepatic insufficiency (HI) meeting a Child-Pugh score of 7 - 9 corresponding to moderate HI were enrolled.

Participant flow — Overall Study
MilestoneModerate Hepatic Impairment (HI)Healthy Controls
Started1010
Completed1010
Not completed00

Outcome measures

SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide

Blood samples were collected at pre-specified time points to determine the AUC0-24 of encilitide. AUC0-24 of encilitide was defined as the area under the concentration-time curve from time 0 to the 24 hours after the dosing of encilitide.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · nM•hr
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide
nM•hrModerate Hepatic Impairment (HI)Healthy Controls
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide131 ± 35.9149 ± 32.4
Statistical analysis
  • Moderate Hepatic Impairment (HI) vs Healthy Controls · Gmr: 0.88 · 90% CI 0.68 to 1.14GMR and 90% confidence interval (CI) were estimated. Geometric Mean Ratio (GMR) = (Test/Reference)
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma

Blood samples were collected at pre-specified time points to determine the AUC0-last of enlicitide in participant's plasma. AUC0 to last of enlicitide was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable (above lower limit of quantitation) concentration. AUC0-last was calculated using noncompartmental analysis.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · nM•hr
Area Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma
nM•hrModerate Hepatic Impairment (HI)Healthy Controls
Area Under the Concentration Versus Time Curve From Time 0 to Last (AUC0-last) of Enlicitide in Plasma486 ± 38.8506 ± 42.7
Statistical analysis
  • Moderate Hepatic Impairment (HI) vs Healthy Controls · Gmr: 0.96 · 90% CI 0.71 to 1.30GMR and 90% confidence interval (CI) were estimated. Geometric Mean Ratio (GMR) = (Test/Reference)
SecondaryTime to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide

Blood samples were collected at pre-specified time points to determine the tmax of enlicitide in participant's plasma. Tmax was defined as time to the maximum concentration of enlicitide reached.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Median · Hour
Time to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide
HourModerate Hepatic Impairment (HI)Healthy Controls
Time to Maximum (Tmax) Observed Plasma Drug Concentration of Enlicitide0.75 (0.50 to 24.13)1.50 (0.50 to 24.28)
SecondaryApparent Terminal Half-life (t1/2) of Enlicitide

Blood samples were collected at pre-specified timepoints to determine the t1/2 of enlicitide. t1/2 was defined as the time required to divide the enlicitide plasma concentration by two after reaching pseudo-equilibrium, following a single dose of enlicitide.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · Hour
Apparent Terminal Half-life (t1/2) of Enlicitide
HourModerate Hepatic Impairment (HI)Healthy Controls
Apparent Terminal Half-life (t1/2) of Enlicitide49.3 ± 14.448.0 ± 20.4
SecondaryApparent Clearance (CL/F) of Enlicitide

Blood samples were collected at pre-specified timepoints to determine the CL/F of enlicitide. CL/F was the apparent total clearance of enlicitide in plasma over time, assessed as the rate at which enlicitide was removed from the plasma.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · Liters/Hour
Apparent Clearance (CL/F) of Enlicitide
Liters/HourModerate Hepatic Impairment (HI)Healthy Controls
Apparent Clearance (CL/F) of Enlicitide23.9 ± 36.723.1 ± 43.8
SecondaryApparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide

Blood samples were collected at pre-specified timepoints to determine the Vz/F of enlicitide. Vz/F was the apparent volume of distribution of enlicitide between the plasma and the rest of the body, after dose, assessed as the total volume of enlicitide that would need to be uniformly distributed to achieve the desired plasma drug concentration.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide
LitersModerate Hepatic Impairment (HI)Healthy Controls
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide1700 ± 47.81600 ± 32.8
SecondaryNumber of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experienced a TEAE were reported.

Time frame:
Up to approximately 6 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
ParticipantsModerate Hepatic Impairment (HI)Healthy Controls
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)00
SecondaryNumber of Participants Who Experienced An Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

Time frame:
Up to approximately 6 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced An Adverse Event (AE)
ParticipantsModerate Hepatic Impairment (HI)Healthy Controls
Number of Participants Who Experienced An Adverse Event (AE)00
SecondaryNumber of Participants Who Discontinued Study Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who discontinued from the study due to an AE were reported..

Time frame:
Up to approximately 6 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Due to an AE
ParticipantsModerate Hepatic Impairment (HI)Healthy Controls
Number of Participants Who Discontinued Study Due to an AE00
PrimaryArea Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide

Blood samples were collected at pre-specified time points to determine the AUC0-inf of enlicitide in plasma. AUC0-inf was defined as AUC0-last + (Cest,last/λz) where Cest, last was the estimated last measurable concentration, and λz was the apparent first-order terminal elimination rate constant.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · nM·hr
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide
nM·hrModerate Hepatic Impairment (HI)Healthy Controls
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Enlicitide540 ± 36.7559 ± 43.8
Statistical analysis
  • Moderate Hepatic Impairment (HI) vs Healthy Controls · Gmr: 0.97 · 90% CI 0.71 to 1.31GMR and 90% confidence interval (CI) were estimated. Geometric Mean Ratio (GMR) = (Test/Reference)
PrimaryMaximum Concentration (Cmax) of Enlicitide

Blood samples were collected at pre-specified time points to determine the Cmax of enlicitide in participant's plasma. Cmax was defined as the maximum observed concentration of enlicitide in plasma after the administration of a given dose.

Time frame:
Predose and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose
Reported as:
Geometric mean · nM
Maximum Concentration (Cmax) of Enlicitide
nMModerate Hepatic Impairment (HI)Healthy Controls
Maximum Concentration (Cmax) of Enlicitide9.07 ± 52.68.81 ± 49.2
Statistical analysis
  • Moderate Hepatic Impairment (HI) vs Healthy Controls · Gmr: 1.03 · 90% CI 0.71 to 1.49GMR and 90% confidence interval (CI) were estimated. Geometric Mean Ratio (GMR) = (Test/Reference)

Adverse events

Collected over Up to approximately 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Hepatic Impairment (HI)0/10 (0%)0/10 (0%)0/10 (0%)
Healthy Controls0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Moderate Hepatic Impairment (HI)Healthy ControlsTotal
Mean60.3 ± 5.3658.7 ± 6.7559.5 ± 5.99
Sex: Female, Male
Sex: Female, Male(Participants)Moderate Hepatic Impairment (HI)Healthy ControlsTotal
Female347
Male7613
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Moderate Hepatic Impairment (HI)Healthy ControlsTotal
Hispanic or Latino9615
Not Hispanic or Latino145
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Moderate Hepatic Impairment (HI)Healthy ControlsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White10919
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Orlando Clinical Research Center ( Site 0002)
    Orlando, Florida 32809, United States
  • The Texas Liver Institute ( Site 0001)
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in May 2025, 7 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 7 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Sep 20, 2024
Primary completionActual
May 1, 2025
CompletionActual
May 8, 2025
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06575959
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Sep 20, 2024
Primary completion
May 1, 2025
Completion
May 8, 2025
Results posted
May 29, 2026
Last update
May 29, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion